Medvi, an AI-powered telehealth startup with just two employees, has achieved staggering financial growth while relying on a marketing strategy that appears to blur the line between medical expertise and artificial intelligence. After generating approximately $401 million in business last year with a profit of $65 million, the company is projected to reach $1.8 billion in sales this year.
However, this rapid scaling is now under scrutiny as evidence emerges of an AI-powered telehealth company Medvi appears to have an AI doctor issue. A review of digital advertising reveals a network of affiliate marketers using AI-generated personas—portraying themselves as medical doctors—to sell weight-loss medications and sexual performance products to unsuspecting consumers.
The discrepancy between the company’s lean operational structure and its massive revenue suggests a highly automated business model. Founder Matthew Gallagher has acknowledged that roughly 30% of the company’s advertising is handled through third-party affiliates. While Gallagher maintains that the company prohibits the undisclosed use of AI portrayals of doctors, the actual execution on social media tells a different story.
The Architecture of ‘Synthetic’ Doctors
The scale of the issue is evident in Meta’s ad library. On a recent Friday, more than 5,000 active ad campaigns linking to Medvi were live. By the following Monday, after the use of AI-generated “doctors” was highlighted, that number dropped to approximately 2,800. The ads featured profiles that bore the hallmarks of generative AI, including garbled text in images and Gemini watermarks on profile photos.
The identities of these purported medical professionals were often incoherent. One profile, “Dr. Matthew Anderson MD,” utilized an Angolan phone number and appeared to have been repurposed from a gospel musician’s page. Another, “Dr. Spencer Langford MD,” contained contact information for a clothing store located in the Republic of Congo. In one instance, a marketer identified as “Wade Frazer MD” removed the medical designation from his profile only after being questioned about his credentials.
Further lapses in verification were found in an account for “Dr. Amelia Rhodes,” which featured imagery of the Johns Hopkins Hospital. However, no individual by that name appears in the Maryland Board of Physicians practitioner database, nor is she listed in the directories of Johns Hopkins Medicine or Johns Hopkins University.
Automating the Patient Funnel
Medvi’s operational efficiency is rooted in a heavy investment in large language models. Gallagher reportedly spent $20,000 in his first month on marketing and AI software, including ChatGPT, Claude, and Grok. These tools were used not only for copywriting but to build the company’s infrastructure and manage customer interactions.
The company’s own website includes a disclaimer stating that “certain materials” are AI-generated or enhanced, and it explicitly disclaims responsibility for the “accuracy, completeness, or reliability” of that content. This hands-off approach extends to the patient experience; some ads suggest patients can secure a prescription in as little as five minutes after completing a “super quick quiz.”
Regulatory Friction and Legal Challenges
The company’s aggressive growth has not gone unnoticed by federal regulators and consumer advocacy groups. In September, the National Consumers League (NCL) and other organizations requested an investigation by the Federal Trade Commission (FTC) into six telehealth companies, including Medvi.
Nancy Glick, the NCL’s director of food, nutrition, and obesity, argues that Medvi’s use of phrases like “doctor-approved” and “trusted by experts” misleads consumers regarding the safety and testing of the compounded drugs the company sells. Glick has characterized the current landscape of online compounded drug sales as a “game of whack-a-mole.”
The FDA also intervened in February, issuing a warning letter regarding representations made on the domain medvi.io. The agency stated that certain claims were “false or misleading,” specifically regarding comparisons to FDA-approved drugs like Wegovy and images that suggested Medvi compounded the drugs itself. Gallagher countered that medvi.io was operated by an unauthorized affiliate and that the company’s official site is medvi.org.
| Event | Detail | Status/Outcome |
|---|---|---|
| FDA Warning Letter | Misleading claims on medvi.io | Website taken down |
| FTC Investigation Request | NCL request regarding deceptive marketing | Requested September |
| Spam Lawsuits | Unsolicited texts and emails | Two pending, one dropped |
| Ad Campaign Purge | Removal of AI-generated doctor profiles | Ads dropped from 5k to 2.8k |
A Pattern of Telehealth Volatility
Medvi’s struggles mirror a broader trend of instability within the telehealth sector, which surged during the COVID-19 pandemic. The industry has seen a massive increase in the distribution of GLP-1 weight-loss medications and ADHD treatments, but this growth has been accompanied by significant legal failures.
Recent precedents include the mental health startup Cerebral, which paid millions to resolve a federal investigation into overprescribing and faced FTC scrutiny over its billing practices. Similarly, the founder of Done, a company focused on Adderall, was found guilty of health-care fraud conspiracy and the illegal distribution of controlled substances.
The core of the issue lies in the “reasonable programs” the FTC requires advertisers to maintain when overseeing affiliates. While Medvi claims to have a clear policy against the undisclosed use of AI actors, the persistence of these ads suggests a gap in oversight. Gallagher has not provided specific details on how the company monitors its affiliate network.
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice.
The company now faces the challenge of reconciling its high-growth, AI-driven model with the stringent requirements of healthcare regulation. The next critical checkpoint will be the outcome of the pending lawsuits regarding spam violations and any potential formal action taken by the FTC following the National Consumers League’s request.
We invite readers to share their experiences with telehealth services and AI-driven medical marketing in the comments below.
